Get informed when a big investor buys or sells
+ FollowOvervalued by 104.8% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $869.99 Million |
|---|---|
| Enterprise Value | $770.57 Million |
| Earnings per Share | $-1.9 |
| Beta | 0.91 |
| Outstanding Shares | 273,582,870 |
| P/E Ratio | -6.4 |
|---|---|
| PEG | 10.67 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 71.41 |
| Enterprise Value to EBIT | -1.76 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 1.13 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Inventiva S.A. is a clinical-stage biopharmaceutical firm dedicated to developing oral small molecule therapies. Its primary therapeutic focus areas include non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various o...